Study #2023-0485
An open-label, multicenter phase 2 study Evaluating the Efficacy and Safety of CRG-022, a CD22-directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Participants with Relapsed/Refractory Large B-Cell Lymphoma after CD19-directed CAR T-cell Therapy
MD Anderson Study Status
Not Accepting
Treatment Agent
Fludarabine (Conditional therapy), Cyclophosphamide Monohydrate (Conditional therapy), firi-cel (Experimental drug)
Description
This is a prospective, open-label, multi-center clinical study designed to evaluate the safety, tolerability, efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity of firicabtagene autoleucel (firi-cel), a CD22-directed autologous Chimeric Antigen Receptor (CAR) T-cell therapy for the treatment of relapsed or refractory large B-cell lymphoma (LBCL).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Cancer, Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Study phase:
Phase II
Physician name:
Sattva Neelapu
Department:
Lymphoma/Myeloma
For general questions about clinical trials:
1-844-737-0154
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.